- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/10 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 207/10
Total number of patents in this class: 170
10-year publication summary
|
11
|
21
|
11
|
8
|
12
|
7
|
9
|
5
|
9
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7832 |
10 |
| 3m Innovative Properties Company | 17536 |
10 |
| Bodor Laboratories, Inc. | 58 |
9 |
| Corteva Agriscience LLC | 2636 |
9 |
| Hoffmann-La Roche Inc. | 3665 |
7 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
5 |
| VALO Health, Inc. | 184 |
5 |
| Daiichi Sankyo Company, Limited | 1881 |
4 |
| Novartis AG | 10376 |
3 |
| Bayer Pharma AG | 1028 |
3 |
| California Institute of Technology | 4011 |
3 |
| KYORIN Pharmaceutical Co., Ltd. | 162 |
3 |
| Taisho Pharmaceutical Co., Ltd. | 859 |
3 |
| Toyama Chemical Co., Ltd. | 94 |
3 |
| Rappta Therapeutics Oy | 9 |
3 |
| Bristol-myers Squibb Company | 4814 |
2 |
| AstraZeneca AB | 2845 |
2 |
| Allergan, Inc. | 2225 |
2 |
| Board of Regents, The University of Texas System | 6018 |
2 |
| The Regents of the University of Michigan | 4890 |
2 |
| Other owners | 80 |